Founded in 2012 and headquartered in Emeryville, California, OmniAb operates as a biotechnology services company specializing in antibody discovery research. The company licenses its proprietary discovery platform to pharmaceutical companies, biotech firms, and academic institutions across the United States, Europe, Japan, China, and Canada. OmniAb's core business involves enabling partners to identify optimal antibodies and target-binding proteins for therapeutic development through screening diverse antibody repertoires.
The company's technology platform centers on Biological Intelligence, which leverages genetically engineered transgenic animals to generate antibodies with human sequences. Its product portfolio includes several engineered animal systems: OmniRat, OmniChicken, and OmniMouse for standard antibody discovery; OmniFlic and OmniClic for bispecific antibody applications; OmniTaur for discovering antibodies against challenging targets using cow-derived structures; and OmnidAb for single-domain antibody discovery. The company also offers OmniDeep, a suite of artificial intelligence and machine learning tools for therapeutic discovery and optimization, alongside partnerships such as its agreement with mAbsolve Ltd. to integrate Fc-silencing technology into its antibody discovery capabilities.
OmniAb operates with approximately 114 full-time employees and is incorporated in Delaware with shares listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.61 | $-0.61 | -19.6% | |
| 2023 | $-0.51 | $-0.51 | -96.2% | |
| 2022 | $-0.26 | $-0.26 | — | |
| 2021 | — | — | — |